159 related articles for article (PubMed ID: 34388137)
21. Epigenetic regulation of integrin β6 transcription induced by TGF-β1 in human oral squamous cell carcinoma cells.
Xu M; Yin L; Cai Y; Hu Q; Huang J; Ji Q; Hu Y; Huang W; Liu F; Shi S; Deng X
J Cell Biochem; 2018 May; 119(5):4193-4204. PubMed ID: 29274289
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer.
Zhuang H; Zhou Z; Ma Z; Li Z; Liu C; Huang S; Zhang C; Hou B
J Cell Mol Med; 2020 Nov; 24(22):13481-13493. PubMed ID: 33073486
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
[TBL] [Abstract][Full Text] [Related]
24. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
25. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
[TBL] [Abstract][Full Text] [Related]
26. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
27. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.
Audisio RA; Veronesi P; Maisonneuve P; Chiappa A; Andreoni B; Bombardieri E; Geraghty JG
Surg Oncol; 1996 Apr; 5(2):49-63. PubMed ID: 8853239
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
30. [Chronic pancreatitis or pancreatic malignancy: clinical and radiological differential diagnosis of pancreas head space-occupying mass].
Nieß H; Albertsmeier M; Thomas M; Kleespies A; Angele M; Bruns CJ
Chirurg; 2013 Feb; 84(2):106-11. PubMed ID: 23400785
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study.
Malesci A; Montorsi M; Mariani A; Santambrogio R; Bonato C; Bissi O; Tacconi M; Wizemann G; Spina G
Pancreas; 1992; 7(4):497-502. PubMed ID: 1641392
[TBL] [Abstract][Full Text] [Related]
35. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
Firpo MA; Gay DZ; Granger SR; Scaife CL; DiSario JA; Boucher KM; Mulvihill SJ
World J Surg; 2009 Apr; 33(4):716-22. PubMed ID: 19082654
[TBL] [Abstract][Full Text] [Related]
36. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
37. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma.
Kobayashi S; Ueno M; Irie K; Goda Y; Aoyama T; Morinaga S; Ohkawa S; Morimoto M
Pancreatology; 2015; 15(5):525-530. PubMed ID: 26255025
[TBL] [Abstract][Full Text] [Related]
38. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
[TBL] [Abstract][Full Text] [Related]
39. Survival analysis of veteran patients with pancreatic cancer.
Kim D; Zhu H; Nassri A; Mokdad A; Kukreja S; Polanco P; Huerta S; Ramzan Z
J Dig Dis; 2016 Jun; 17(6):399-407. PubMed ID: 27235863
[TBL] [Abstract][Full Text] [Related]
40. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
